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COMMENTARY
Adolescent HPV vaccination: empowerment, equity and ethics
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ABSTRACT
Despite the great promise offered by human papillomavirus (HPV) vaccines to reduce disease burden
and promote socioeconomic and gender equality, their implementation into national programmes has
been slow. The vaccination of adolescents against a disease that may have serious consequences much
later in life requires special consideration to the principles and processes of informed consent.
Accumulating experiences from implementations in many countries indicate a need to examine ethical
considerations related to adolescent vaccination. However, frameworks that integrate legal, develop-
ment- and rights-based considerations in adolescent vaccination policies, while taking into account
practical realities of HPV vaccination programmes, are currently lacking. We argue that principles of
autonomy, social justice and gender equality have impacts on adolescent immunization that go beyond
mere acceptance of vaccination and place greater demands on what constitutes meaningful informed
consent, with implications for the provision of age- and context-appropriate information, vaccine
financing and gender-based vaccination policies. Independent of cost-effectiveness considerations, we
find a strong case to support universal HPV vaccination of girls that is free at the point of use and, where
feasible, to extend vaccination to boys under the same financing schemes.
Abbreviations: HPV: Human papillomavirus; STI: Sexually transmitted infections; WHO: World Health
Organization
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Background
The World Health Organization (WHO) recommends vaccina-
tion of girls aged 9–14 years against human papillomavirus
(HPV).1 Effective HPV vaccines have been available for over
10 years and have been shown to reduce the risk of cervical
infection with high-risk HPV types by over 90%, and the risk of
genital warts by over 80% among women who receive a full
course of vaccination.1 HPV vaccination programmes aimed at
girls in this age group are likely to be highly cost-effective in
most settings.2 But despite notable successful national HPV
immunization programmes, both in high- and low-income
countries, HPV vaccination has yet to be introduced nationally
in many countries, including most countries in Africa and Asia.3
Half a million cervical cancer cases and a quarter of a million
cervical cancer deaths are caused by HPV worldwide each year.4
Of these, more than 80% occur in low- and middle-income
countries, and women in the most economically productive
age groups are disproportionately affected.5 HPV vaccine imple-
mentation is thus not simply an urgently-needed public health
intervention – it is a development and equity issue.
Challenges affecting the roll-out and uptake of HPV vacci-
nation have been described from numerous countries.
Although these differ widely between settings, they include,
among others, lack of infrastructure to support a national
programme, insufficient political will, high vaccine
procurement and delivery cost at the national level, and
inadequate involvement from healthcare professionals in
recommending the vaccine at the provider level.6,7
Additionally, HPV vaccines have met resistance from certain
groups who express a lack of confidence in or distrust of these
vaccines, because they are perceived to be relatively new, are
(inaccurately) portrayed as unsafe and ineffective, and are
given to adolescents to protect against a sexually-transmitted
infection, which may raise unwelcome discussions regarding
adolescent sexual behavior.7,8
HPV vaccination is recommended before the age of sexual
debut, because the vaccine is expected to be less effective after
an individual is exposed to HPV. HPV vaccine is unique in
that, although consent to vaccinate adolescents is typically
sought from those with parental responsibility, the benefits
to individuals in terms of cancer prevention are not apparent
until several decades later, once those adolescents have
already reached the legal age of consent and when it may be
too late to vaccinate. This is in stark contrast to vaccinations
delivered in early childhood, which are primarily intended to
protect against infections in the first few years of life, when
children cannot reasonably be expected to make informed
decisions about their healthcare.
Vaccination of adolescents requires additional considera-
tions for the principles and processes of informed consent,
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not least for school-based programmes in which vaccination is
administered without the presence of parents or legal guar-
dians. The WHO has issued considerations regarding consent
for vaccination in children and adolescents,9 but these do not
address certain issues specific to HPV vaccination. Existing
position papers and considerations regarding adolescent vac-
cination pay particular attention to legal aspects of consent in
minors.9,10 Others have argued for the importance of adopting
a rights-based approach to adolescent vaccination,11 in line
with the United Nations Convention on the Rights of the
Child, which emphasizes childrens’ rights to have their best
interests considered in societal decisions, to achieve optimal
survival and development, to express opinions freely, to have
access to information and act on it, to have their privacy
respected, and to have access to the highest standard of
healthcare.12 More broadly, the Sustainable Development
Goals underpin a global commitment to policies that reduce
gender and economic inequality. Despite these individual
guidelines and global goals, frameworks that integrate these
legal, development- and rights-based considerations in ado-
lescent vaccination decisions, while taking into account the
practical realities of HPV vaccination programmes, are cur-
rently lacking.
While others have used ethical13 and social justice14 per-
spectives to explore the scope and financing of HPV vaccina-
tion programmes, we seek to extend these views in light of
accumulating experiences from implementations in an
increasing number of countries. In this paper, we argue that
HPV vaccination is unlike other vaccinations currently admi-
nistered to adolescents, both in its purpose and the long-term
benefits and consequences of vaccination, and that this has
far-reaching implications that make greater demands on the
informed consent process. We therefore begin with an exam-
ination of what constitutes informed consent in the context of
adolescent HPV vaccination and the implications for infor-
mation provision and models of consent. We subsequently
discuss the consequences that these greater demands on the
informed consent process have for both vaccine financing and
gender-based vaccination policies in adolescents.
Consent
In certain areas of healthcare, precedent exists to consider and
respect adolescents’ increased capacity for making healthcare
decisions, including access to sexual and reproductive health
services. In some settings, adolescents have legal rights to seek
contraceptive advice, access diagnosis and treatment for sexu-
ally transmitted infections (STI), or seek pregnancy termina-
tion without parental knowledge or consent if they are
deemed to be sufficiently mature and intelligent to under-
stand the nature and implications of a proposed intervention.
These are based on the common law rules of Gillick compe-
tence (in the UK) or the mature minor doctrine (in the US
and Canada), or similar jurisdiction-specific statutory law.
Adolescents’ rights in the area of vaccination have received
less attention. Whether adolescents should have the right to
self-consent for HPV vaccination is a subject of debate,15
despite it being an intervention for STI prevention.11 In set-
tings where Gillick competence may provide the legal basis for
adolescent self-consent, immunization providers have been
found to be reluctant to vaccinate without obtaining written
parental consent first.16 However, the epidemiological char-
acteristics of HPV as an infection that has major health con-
sequences predominantly in women, the potential for an
adolescent vaccine to prevent disease beyond the age of
majority, and the increasing capacity of adolescents to make
informed decisions regarding their own healthcare, supports
a greater role for adolescents in decision-making and consent
for vaccination. The limited available empirical evidence from
studies in adolescents indicates that a substantial fraction of
individuals aged 10 to 15 years consider themselves suffi-
ciently mature to make vaccination decisions17,18 and that,
from adolescents’ perspectives, cooperation with vaccination
does not equate to consent.18 Another study found that chil-
dren above the age of 11 years can be considered fully com-
petent in medical decision-making and using age as a guide
for decision-making capacity is reasonable.19
Adolescents’ decision-making capacity should not in itself
ethically or legally justify their decisional authority,20 as there
may be good reasons in a given society or context to invest
decisional authority in parents or ensure their involvement for
certain healthcare decisions. For example, vaccinations other
than HPV are commonly administered to adolescents, includ-
ing booster doses of diphtheria, tetanus and pertussis vac-
cines, and in some settings meningococcal and seasonal
influenza vaccines. These serve three main functions – to
counter waning immunity in individuals, immunize indivi-
duals who may have been missed earlier, or prevent outbreaks
in higher-risk settings like schools and universities. These
functions have implications that have bearing on the nature
of consent for vaccination, which is generally granted by
parents. Firstly, booster doses are, in most individuals, inter-
ventions that have already been administered in similar form
earlier in life, and are thus part of completing a course of
a vaccination to which parents have already consented.
Secondly, particularly in the case of infections transmitted
through the respiratory route or through close contact, the
prevention of outbreaks is a collective responsibility; indivi-
dual adolescents have limited agency to prevent exposure to
or transmission of influenza virus or Bordetella pertussis, for
example, and so cannot be expected to bear responsibility for
outbreak prevention. In this circumstance, we believe there is
a stronger ethical case for the responsibility of consent to rest
primarily with parents or those with legal authority.
We see four key distinctions in the case of HPV vaccina-
tion that differentiate it from these other adolescent vaccines.
Firstly, HPV vaccination is intended to reduce the risk of
infection and disease from a sexually-transmitted infection,
exposure to which is less institutionally-dependent and may
happen not just in adolescence but well beyond the legal age
of consent. Secondly, alternative ways exist to prevent HPV
infection, including abstaining from sexual activity and safer
sex practices to reduce infection risk. Implicit in these alter-
natives are issues of gender and power relations that are
relevant when assessing their effectiveness, as well as a need
to recognize that contextual factors may moderate one’s abil-
ity to negotiate sexual interactions that may influence indivi-
dual risk of infection. Greater agency over these alternatives
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means greater responsibility to self and to others, but also
means that individuals should be better informed about those
responsibilities, so that they can make more informed deci-
sions when choosing among a set of alternative or comple-
mentary preventive measures. Thirdly, HPV vaccination has
implications for health needs and behaviors in later life, par-
ticularly cervical cancer screening. Fourthly, the major disease
manifestation, cervical cancer, primarily occurs in adulthood,
when its impact is particularly acute, as it affects women at
a time in their life when they are typically at their most
economically productive and when they may also bear
responsibility over others, including children. These consid-
erations augment the case for allowing adolescents to have
greater influence in vaccination decision-making and consent,
rather than placing responsibility solely on parents.
It is important to note, however, that both Gillick compe-
tence and the mature minor doctrine prescribe the need for
parental involvement unless it is contrary to the best interests
of the minor.21 Examples are when the parents are unavailable
or unwilling to provide consent when the minor would like to
receive an intervention, would benefit from it, and would
otherwise be harmed if it were withheld. This ethico-legal
understanding notwithstanding, the moral need to include
adolescents in the informed consent process is particularly
strong for HPV vaccination, given the potentially serious
implications in the later life of an adolescent being denied
vaccination. There is therefore a strong case favoring the active
involvement of adolescents and the inclusion of their views in
the informed consent process, even in jurisdictions where
parental consent is the default requirement for general medical
care. The exact mechanism of consent for HPV vaccination
may vary between settings and may involve opt-in or opt-out,
written or verbal, implicit or explicit approaches. Regardless of
the specific mechanism and legal responsibility for consent,
adolescent involvement in HPV vaccination should go beyond
the moral concept of pediatric assent, which in the context of
large-scale vaccination programmes may often be taken as
a child’s acceptance of vaccination. Involving adolescents in
the informed consent process means that adolescents should be
free to express their views regarding their own vaccination, be
entitled to have those views heard, have influence over the
decision of whether or not to vaccinate, and share in the
responsibility for that decision.
Our practical recommendations are as follows. In settings
where written consent is required and where there is legal
basis, adolescents should be allowed to self-consent to HPV
vaccination as a right. Alternatively, a dual consent approach
with equal weight given to parent and adolescent decisions could
be implemented, particularly if there is general reluctance among
providers or adolescents themselves to rely on adolescent self-
consent alone. In all settings, adolescents, including those with-
out decision-making capacity, should be adequately informed
about the benefits and consequences of HPV vaccination, as well
as what they should expect during the vaccination process itself.
Importantly, information should be age-appropriate. Evidence
from both high- and low-middle income settings indicates that
there is a need to improve awareness and knowledge of HPV
vaccination among adolescents.22,23 In an evaluation of the
school-based HPV vaccination programme in Australia,
adolescents reported that although information on the vaccine
was provided, this was targeted at adults and not easy for
adolescents themselves to comprehend.24 Furthermore, infor-
mation provided to adolescents should include considerations
of the benefits and risks of vaccination, the consequences of
a decision to vaccinate or not vaccinate, and the implications
for cancer screening later in life. In addition, the potential impact
of vaccine delivery itself should be communicated.25 Few studies
have sought to understand HPV vaccination programmes from
the perspective of adolescents being vaccinated. Studies from
Australia reported a number of challenges in the delivery of
school-based HPV vaccination, including anxiety among stu-
dents resulting from fear of injection pain, having to wait for
extended periods, as well as difficulties in maintaining privacy.24
The latter could be particularly important for HPV vaccine, as
pregnancy status may need to be determined at the time of
vaccination, the unintentional disclosure of which could result
in individuals being stigmatized and could have serious legal
ramifications in some settings. Anxiety resulting from the spread
of rumors among students has also been reported by some
studies,26 while in some settings mass psychogenic events result-
ing from large-scale HPV vaccination have been
documented.27,28 Integrating respect for privacy as a key aspect
in the processes of consent and delivery, and targeting informa-
tion at adolescents could directly address these issues and make
adolescents better informed about what to expect during the
vaccination process.
Vaccine financing
Equitable access to HPV vaccines within and between settings
is intrinsically linked with social justice, given the potential of
these vaccines to address serious medical, economic and social
challenges arising from cervical cancer in women. Access to
vaccines, however, is intimately linked to vaccine financing and
cost. Studies of young women and parents of adolescents
repeatedly find that high vaccine cost is a major barrier to
HPV vaccination.29,30 Malmqvist et al. discuss ethical consid-
erations for various possible models for financing adolescent
HPV vaccination, ranging from an individual-initiated model
in which vaccination is paid for entirely out-of-pocket, to
a fully publicly-funded model mandating vaccination of both
girls and boys.13 We do not repeat these here, but argue that
greater involvement of adolescents in vaccination decisions
additionally has important consequences for vaccine financing.
Giving adolescents greater agency in vaccination decisions
through appropriate information provision and self-consent,
dual consent or shared decision-making processes, may
become moot in situations in which financial constraints affect
the decision. By and large, adolescents do not have themeans to
pay for healthcare interventions, so financial barriers to vaccine
access introduce severe asymmetries to adolescents’ say in
vaccination decision-making, since adolescents are unable to
pay for the vaccine even if they wish to have it, while parents
might discourage or refuse vaccination on the basis of cost.
This severely impinges on adolescents’ autonomy (their gov-
ernance over their own body and health), since it introduces
the potential for vaccination decisions to be dependent on
affordability, over which adolescents generally have no control.
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Decisions based on individual affordability could also have
other negative impacts. In school-based programmes where
HPV vaccines are not provided for free, inequity in vaccine
access has the potential to introduce stigma among students in
lower income groups. At the population level, individuals’
inability to pay for HPV vaccine is likely to further widen
health and financial disparities based on gender and socio-
economic position, particularly in settings where access to
cancer screening is also limited.31 By contrast, analyses indicate
that publicly-funded HPV vaccination is likely to promote
greater equity by affording proportionately greater health ben-
efits to lower income groups. Publicly-funded HPV vaccination
programmes have also been shown to result in higher coverage
compared with programmes in which individuals pay out of
pocket.29 Higher coverage is likely to have additional benefits,
including indirect protection of unvaccinated individuals
through herd immunity and encouraging vaccination as nor-
mative behavior. Conversely, having to pay for the vaccine may
give individuals the impression that it is less of a priority
compared with other publicly-funded vaccines.
Gender-based vaccination
Among countries with national adolescent HPV vaccination
programmes, only a minority have extended universal vacci-
nation to adolescent boys. In some countries, the vaccine is
recommended for adolescent boys, but whether it is publicly
funded or paid for out of pocket may depend on sub-national
vaccination policies or insurance coverage. In still other coun-
tries, HPV vaccine may be licensed for adolescent boys, but
must be paid for out of pocket, regardless of whether public
financing exists for vaccination of adolescent girls. Arguments
in favor of girls-only vaccination are based on the fact that
females are disproportionately affected by the health effects of
HPV, that heterosexual males will be largely protected from
HPV infection by herd immunity if vaccine coverage in
females is sufficiently high, as well as lack of conclusive
evidence regarding the cost-effectiveness of extending vacci-
nation to boys.32
Cost-effectiveness analyses weigh up the cost of imple-
menting a new vaccination programme against the societal
burden of avoidable morbidity and mortality. Such analyses
are increasingly used to provide objective metrics for inform-
ing vaccination policies. In settings with large private health
sectors, however, cost-effectiveness assessments may be less
clear cut, because while the state is usually responsible for
decisions regarding vaccine introduction, the costs of vaccina-
tion and the healthcare costs of avoidable illness may be
shared by a mixture of public financing, private insurance
and out-of-pocket payments. Cost-effectiveness analyses gen-
erally do not capture how much these different actors are
willing to pay to avoid illness, or broader societal benefits
resulting from greater gender equity and reduced socioeco-
nomic disparities. Furthermore, given a certain disease bur-
den, vaccine efficacy profile and price, cost-effectiveness is
dependent on a minimum level of vaccination coverage
being reached, which is more difficult to achieve if the pro-
gramme is not publicly funded and implemented. Current
evidence indicates that increasing coverage in girls is more
cost-effective than offering gender-neutral vaccination, as girls
only vaccination offers direct protection against cervical can-
cer and indirectly protects males against HPV infection.
Extending vaccination to boys could be cost-effective in set-
tings with low vaccination coverage in girls.33,34 Particularly
in settings where female HPV vaccination coverage is modest
and difficult to increase, there may be a strong scientific case
for extending vaccination to boys with the same financing
mechanisms as those available for vaccinating girls.
Notwithstanding these cost-effectiveness considerations,
strong arguments exist for extending universal, publicly-
funded HPV vaccination to adolescent boys based on princi-
ples of autonomy, social justice and gender equity.13 Although
the health burden from HPV disproportionately affects
women and the priority should be to increase vaccination
coverage in girls, an argument could be made that adolescent
boys should reasonably expect the direct benefits of vaccina-
tion rather than rely on indirect protection that depends on
the vaccination and sexual behavior of others. In addition,
HPV still causes a substantial disease burden in men. A recent
study from the United States found a 3-fold higher prevalence
of oral HPV infection in men compared with women,35 and
men have a higher risk of certain HPV-related cancers, such
as head and neck cancers, that are increasing in incidence in
many regions.4 While burden in heterosexual men may be
decreased given high female HPV vaccine coverage, the exis-
tence of certain male groups at higher risk of HPV infection
and disease, such as men who have sex with men, could be an
argument in favor of more equitable strategies specifically
focusing on these groups. However, identifying individuals
in these groups during early adolescence may be difficult
and could have legal implications in some settings, while
delaying vaccination until after sexual debut is likely to
decrease vaccine effectiveness.
Secondly, while women may experience the bulk of HPV-
related disease burden, both men and women contribute to
HPV transmission. Given that there is no substantive gender
difference in the profile of HPV vaccines in terms of safety
and effectiveness against HPV infection, implementing girls-
only vaccination places the burden for HPV prevention over-
whelmingly on women. Men benefit from indirect protection
when female vaccination coverage is high without taking on
any potential risks (albeit minimal) associated with vaccine
adverse effects, despite the existence of a means for them to
contribute to prevention of HPV infection and disease. Such
‘free-riding’ seems at the very least to be morally questionable.
Extending universal vaccination to adolescent boys promotes
their ability to contribute to a public good that leads to a net
benefit for each individual person vaccinated, and which
would not make the community worse off in general from
a public health ethics perspective.36
Finally, much controversy regarding HPV vaccination and
reluctance to vaccinate has resulted from societal perceptions
that vaccination encourages earlier sexual debut, increases sexual
activity or promotes risky sexual behavior, particularly among
adolescent girls. Numerous studies have failed to provide evi-
dence for such behavioral changes in either gender.37,38 By con-
trast, studies have found support for HPV vaccination of boys
from community members, parents and healthcare providers,
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who consider this an important way to emphasize boys’ respon-
sibilities toward sexual health and reduce gender-based stigma
surrounding sexual activity.39 Indirectly, therefore, a gender-
neutral approach promotes the moral norm of a shared respon-
sibility in all adolescents regardless of gender, while reducing
misconceptions of girls as having principal responsibility for
HPV transmission and prevention, potentially increasing consent
for vaccination and improving vaccine uptake.
Conclusions and recommendations
Adolescent consent for HPV vaccination is intrinsically related
to vaccine financing and principles of health and gender equity.
Respect for adolescents’ autonomy requires that due considera-
tion be given to how vaccine financing impinges on adolescents’
capacity to influence decisions about their own future health.
Furthermore, commitments to reducing global health inequal-
ities need to recognize the unique role that HPV vaccines can
play in promoting both health and gender equity. On this basis,
we believe that there are strong ethical and scientific grounds in
support of universal vaccination of adolescent girls against HPV
that is free at the point of use. In settings where it is feasible,
extending vaccination to adolescent boys should be considered
on the basis that these are likely to bring about societal benefits
beyond simply cost-effectiveness, including promoting adoles-
cent vaccination as normative behavior, reducing gender-based
stigma related to vaccination, and a sense of shared responsi-
bility for HPV prevention. Where vaccine coverage among girls
is low and difficult to increase, these arguments are further
strengthened by increased cost-effectiveness of extending vacci-
nation to both genders. Where HPV vaccination is not fully
publicly funded but financed partly through subsidies or reim-
bursements, there is a strong equity argument for making HPV
vaccines available to both girls and boys through the same
financing mechanisms.
Our central argument focuses on what should be under-
stood to constitute meaningful informed consent in the con-
text of HPV vaccination, which we take to include the
provision of age-appropriate information regarding the bene-
fits, consequences and process of HPV vaccination, as well as
the active inclusion of adolescents’ views in vaccination deci-
sions, regardless of existing legal frameworks of consent. Our
arguments and conclusions are therefore not limited to any
specific setting. The extent to which adolescents are actively
involved in decision-making about HPV vaccination, beyond
simply pediatric assent, is difficult to assess and may (perhaps
appropriately) vary across families. Further research in this
area and experience from HPV vaccine implementing coun-
tries will be highly informative for developing guidance on
how best to respect adolescents’ autonomy and privacy while
safeguarding their best interests throughout the consent and
vaccine delivery processes. The consent process should at the
very least include age-appropriate information for adolescents
on benefits and consequences of vaccination, as well as infor-
mation regarding what to expect during the process of vaccine
delivery. Although the role of adolescents in spreading nega-
tive perceptions about vaccination has been well
documented,26,40 adolescents’ potential role in promoting
positive attitudes to vaccination, for example through the
sharing of positive vaccination experiences with unvaccinated
peers, has received little attention and warrants further
research. Valuing and empowering adolescents in this way
not only affirms their role as engaged and active contributors
to decision making, but also fulfills a strategic objective of the
Global Vaccine Action Plan that “individuals and communities
understand the value of vaccines and demand immunization as
both their right and responsibility”.
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